British journal of cancer · 2026
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shaaban Aya Elhusseiny, Jourdain Hugo, Desplas David, Vignot Stéphane, Zureik Mahmoud, Haddy Nadia
Аннотация
BACKGROUND: Sacituzumab govitecan (SG) was granted early access in France as third-line therapy for metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-mBC) metastatic breast cancer. This nationwide cohort study assessed its real-world use and survival outcomes.
METHODS: Using the French National Health Data System, we included all patients initiating SG between July 1, 2021, and December 31, 2023, with follow-up until June 30, 2024. Patient demographics, comorbidities, and prior treatments were recorded. Overall survival (OS) and time to treatment discontinuation (TTD) were estimated by Kaplan-Meier methods, and multivariable Cox models identified OS prognostic factors.
RESULTS: 3653 patients were included: 2527 mTNBC and 1,126 HR+/HER2- mBC, with median ages of 58 and 61.5 years. Median OS was 11.0 months (95%CI: 10.4-11.7) for mTNBC and 11.4 months (95% CI: 10.7-12.4) for HR+/HER2-mBC. One-year survival was 47% and 48% and median TTD of 4.3 and 3.5 months, respectively. Poorer OS was independently associated with inpatient SG initiation and liver/digestive metastases. In mTNBC, additional factors included brain metastases, respiratory disease, tobacco-related hospitalisation, multiple metastatic sites, and prior treatments.
CONCLUSION: The study highlights SG's clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.
METHODS: Using the French National Health Data System, we included all patients initiating SG between July 1, 2021, and December 31, 2023, with follow-up until June 30, 2024. Patient demographics, comorbidities, and prior treatments were recorded. Overall survival (OS) and time to treatment discontinuation (TTD) were estimated by Kaplan-Meier methods, and multivariable Cox models identified OS prognostic factors.
RESULTS: 3653 patients were included: 2527 mTNBC and 1,126 HR+/HER2- mBC, with median ages of 58 and 61.5 years. Median OS was 11.0 months (95%CI: 10.4-11.7) for mTNBC and 11.4 months (95% CI: 10.7-12.4) for HR+/HER2-mBC. One-year survival was 47% and 48% and median TTD of 4.3 and 3.5 months, respectively. Poorer OS was independently associated with inpatient SG initiation and liver/digestive metastases. In mTNBC, additional factors included brain metastases, respiratory disease, tobacco-related hospitalisation, multiple metastatic sites, and prior treatments.
CONCLUSION: The study highlights SG's clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.